

Status: Currently Official on 16-Feb-2025
Official Date: Official as of 01-May-2018
Document Type: USP Monographs
DocId: GUID-CF6DCEE9-9C3D-46FA-B2CB-BFDC1816C265_3_en-US
DOI: https://doi.org/10.31003/USPNF_M81620_03_01
DOI Ref: wq6zd

© 2025 USPC
Do not distribute

Tetracaine Hydrochloride Injection

DEFINITION

Tetracaine Hydrochloride Injection is a sterile solution of Tetracaine Hydrochloride in Water for Injection. It contains NLT 95.0% and NMT 105.0% of the labeled amount of tetracaine hydrochloride ($C_{15}H_{24}N_2O_2 \cdot HCl$).

IDENTIFICATION

- **A.**

Sample solution: 100 mg in 10 mL of water

Analysis: To the *Sample solution* add 1 mL of potassium thiocyanate solution (1 in 4). A crystalline precipitate is formed. Recrystallize the precipitate from water, and dry at 80° for 2 h.

Acceptance criteria: The crystalline precipitate melts between 130° and 132°.

• **B.** The retention time of the major peak of tetracaine in the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

- **PROCEDURE**

Mobile phase: Acetonitrile, methanol, and water (20:20:60) containing 0.06% of sulfuric acid, 0.5% of sodium sulfate, and 0.02% of sodium 1-heptanesulfonate. The pH is about 2.6.

Diluent: Methanol and water (1:1)

Standard solution: 1 mg/mL of [USP Tetracaine Hydrochloride RS](#) in *Diluent*

System suitability solution: 4 mg/mL of salicylic acid and 1 mg/mL of tetracaine hydrochloride in *Standard solution*

Sample solution: Nominally 1 mg/mL of tetracaine hydrochloride in *Diluent* from *Injection*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 305 nm

Column: 3.9-mm × 30-cm; packing L1

Flow rate: 2 mL/min

Injection volume: 5 μ L

System suitability

Samples: *System suitability solution* and *Standard solution*

[**NOTE**—The relative retention times for salicylic acid and tetracaine are about 0.8 and 1.0, respectively.]

Suitability requirements

Resolution: NLT 2 between salicylic acid and tetracaine peaks, *System suitability solution*

Relative standard deviation: NMT 2.0% for replicate injections, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of tetracaine hydrochloride ($C_{15}H_{24}N_2O_2 \cdot HCl$) in the portion of *Injection* taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of tetracaine from the *Sample solution*

r_S = peak response of tetracaine from the *Standard solution*

C_S = concentration of [USP Tetracaine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of tetracaine hydrochloride in the *Sample solution* (mg/mL)**Acceptance criteria:** 95.0%–105.0%**SPECIFIC TESTS**

- **PARTICULATE MATTER IN INJECTIONS (788):** Meets the requirements for small-volume injections
- **BACTERIAL ENDOTOXINS TEST (85):** NMT 0.7 USP Endotoxin Units/mg of tetracaine hydrochloride
- **pH (791):** 3.2–6.0
- **OTHER REQUIREMENTS:** It meets the requirements in *Injections and Implanted Drug Products (1)*.

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in single-dose or in multiple-dose containers, preferably of Type I glass, under refrigeration and protected from light. It may be packaged in 100-mL multiple-dose containers. Injection supplied as a component of spinal anesthesia trays may be stored at room temperature for 12 months.
- **LABELING:** Label it to indicate that the Injection is not to be used if it contains crystals, or if it is cloudy or discolored.
- **USP REFERENCE STANDARDS (11):**
[USP Tetracaine Hydrochloride RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
TETRACAIN HYDROCHLORIDE INJECTION	Documentary Standards Support	SM52020 Small Molecules 5
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM52020 Small Molecules 5

Chromatographic Database Information: [Chromatographic Database](#)**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. Information currently unavailable

Current DocID: GUID-CF6DCEE9-9C3D-46FA-B2CB-BFDC1816C265_3_en-US**Previous DocID: GUID-CF6DCEE9-9C3D-46FA-B2CB-BFDC1816C265_1_en-US****DOI: https://doi.org/10.31003/USPNF_M81620_03_01****DOI ref: [wq6zd](#)**